No products in the cart.
Mechlorethamine Hydrochloride Injection
$1.00
Mechlorethamine hydrochloride (HaiPu®) is a potent DNA-alkylating agent from the nitrogen mustard class, supplied as a 1mL vial containing 5mg. Manufactured by Shanghai Xudong Haipu Pharmaceutical Co., Ltd., with NMPA approval H31020897 and product code 86900808000625. Strictly for laboratory research use.Please consult the staff for other purposes.
Description
Mechlorethamine-Hydrochloride-Injection Specifications
| Attribute | Details |
|---|---|
| Product Name | Mechlorethamine Hydrochloride Injection |
| Concentration | 5mg mechlorethamine hydrochloride per 1mL vial |
| Dosage Form | Injectable solution (vial) |
| Approval No. | China NMPA H31020897 |
| Product Code | 86900808000625 |
| Manufacturer | Shanghai Xudong Haipu Pharmaceutical Co., Ltd. |
| Intended Use | Laboratory research use only—Not for human or veterinary use |
Mechlorethamine Hydrochloride Injection Background & Mechanism
Mechlorethamine is a nitrogen mustard alkylating agent that induces DNA cross-linking to inhibit DNA synthesis and trigger apoptosis. Its powerful cytotoxic nature stems from forming bifunctional adducts with DNA, particularly guanine residues . Although once used clinically, its high toxicity led to a decline in therapeutic use, making it largely a research chemical today .
Mechlorethamine Hydrochloride Injection Safety & Storage
Carcinogenicity warning: Classified as a probable human carcinogen ntp.niehs.nih.gov.
Storage: Protect from light; store in tightly sealed vials; may degrade quickly in solution.
Handling: Use lab-grade PPE (gloves, gown, eye protection). Administer only in ventilated biosafety cabinets due to inhalation and contact hazard.
Mechlorethamine-Hydrochloride-Injection Research Applications
DNA crosslinking assays
Cytotoxicity screening and DNA damage studies
Modeling alkylation-based genotoxic stress
Mechanisms of repair pathway research (e.g., NER, HR)
Disclaimer
This product is provided strictly for laboratory research and development use only. Not intended for human, veterinary, clinical, diagnostic, or therapeutic applications.
Additional information
| Weight | 1.1 kg |
|---|---|
| Dimensions | 18 × 18 × 16 cm |
1 review for Mechlorethamine Hydrochloride Injection
Q1:Mechlorethamine Hydrochloride Injection Can this be used for clinical treatment?
A1: No—strictly for laboratory research only, not intended for therapeutic, diagnostic, or veterinary use.
Q2: How does it work in cells?
A2: It alkylates DNA at guanine N7 positions, causing cross-links that prevent replication and lead to apoptosis
Q3: What are the main safety concerns?
A3: Highly toxic and carcinogenic. Requires strict handling protocols, disposal procedures, and protective equipment.
Q4: How should it be stored and prepared?
A4: Keep in original vial, protected from light, and refrigerated when not in use. Reconstitute under biosafety conditions and use immediately due to instability.
Q5: Can you provide SDS or COA documentation?
A5: Yes—available upon request for qualified research labs.
Related products
Clodronate Disodium Capsules
Clodronate Disodium Capsules are a bisphosphonate medication used to inhibit osteoclast-mediated bone resorption. Manufactured by Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. and approved by China’s NMPA (National Medical Products Administration) under approval number H19980041. $2.00Elranatamab Injection
Elranatamab (ELREXFIO®) is a BCMA-CD3 bispecific antibody used in multiple myeloma research. Supplied as a 76mg/1.9mL single-dose vial, manufactured by Pfizer. Approved by FDA (Aug 2023) and EMA (Dec 2023). Ideal for oncology, immunotherapy, and Tcell engager studies.
$1.00Propranolol Hydrochloride Oral Solution
Propranolol Hydrochloride Oral Solution (HeMeiJia) offers a sweet strawberry-mint 40mg/5mL formulation in a 40mL bottle. Approved by NMPA under H20213549, this solution provides accurate dosing—ideal for infantile hemangioma, pediatric cardiovascular, or pharmacokinetic studies.
$1.00Limertinib Tablets
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M mutated non small cell lung cancer, including patients with brain metastases. $1.00
naythan –
thank you bro